Sugi Predict

Sugi Predict / Compounds / SCHEMBL10085201

SCHEMBL10085201

SCHEMBL10085201

CC(C)(C)OC(=O)Nc1ccnc(Cl)c1C=O

nearest known ligand 0.55

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ ATR Q13535 1/20 0.55
▸ METAP1 P53582 1/20 0.41
▸ CYP17A1 P05093 3/20 0.40
▸ RAB9A P51151 2/20 0.38
▸ AAK1 Q2M2I8 3/20 0.37
▸ MAPKAPK2 P49137 1/20 0.37
▸ NPC1 O15118 1/20 0.37
▸ LMNA P02545 1/20 0.37
▸ TP53 P04637 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ POLB P06746 1/20 0.36
▸ NAMPT P43490 1/20 0.36
▸ MIF P14174 1/20 0.36
▸ HSP90AA1 P07900 1/20 0.36
▸ HSP90AB1 P08238 1/20 0.36
▸ TRPA1 O75762 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31146037 0.88 ATR (0.48) ATRMETAP1CYP17A1RAB9AAAK1
SCHEMBL30868981 0.87 ATR (0.47) ATRMETAP1CYP17A1RAB9AAAK1
SCHEMBL30888170 0.84 ATR (0.59) ATRMETAP1CYP17A1AAK1MAPKAPK2
SCHEMBL30937539 0.84 ATR (0.47) ATRMETAP1CYP17A1RAB9AAAK1
SCHEMBL4393718 0.83 ATR (0.58) ATRMETAP1CYP17A1AAK1MAPKAPK2
SCHEMBL1866287 0.83 ATR (0.58) ATRMETAP1CYP17A1AAK1MAPKAPK2
SCHEMBL31672835 0.83 ATR (0.43) ATRMETAP1CYP17A1RAB9ANAMPT
SCHEMBL30868854 0.83 ATR (0.43) ATRMETAP1CYP17A1MAPKAPK2NAMPT
SCHEMBL27386016 0.83 ATR (0.43) ATRMETAP1CYP17A1RAB9ANAMPT
SCHEMBL797495 0.82 ATR (0.56) ATRMETAP1CYP17A1AAK1MAPKAPK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024075696-A1 IMIDAZOPYRIDINE DERIVATIVES WITH BICYCLIC STRUCTURE 公立大学法人横浜市立大学 2024-04-11 — — WO disclosed
US-20230322724-A1 HETEROCYCLIC COMPOUNDS AS CBP/EP300 BROMODOMAIN INHIBITORS AURIGENE ONCOLOGY LIMITED (IN) 2023-10-12 — — US disclosed
US-20230322724-A1 HETEROCYCLIC COMPOUNDS AS CBP/EP300 BROMODOMAIN INHIBITORS AURIGENE ONCOLOGY LIMITED (IN) 2023-10-12 — — US disclosed
US-20230322724-A1 HETEROCYCLIC COMPOUNDS AS CBP/EP300 BROMODOMAIN INHIBITORS AURIGENE ONCOLOGY LIMITED (IN) 2023-10-12 — — US disclosed
EP-4210683-A1 HETEROCYCLIC COMPOUNDS AS CBP/EP300 BROMODOMAIN INHIBITORS Aurigene Oncology Limited (IN) 2023-07-19 — — EP disclosed
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 — — US disclosed
WO-2022053967-A1 HETEROCYCLIC COMPOUNDS AS CBP/EP300 BROMODOMAIN INHIBITORS AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) 2022-03-17 — — WO disclosed
EP-2303269-B1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME (US) 2014-07-30 — — EP disclosed
US-20130287763-A1 COMBINATION THERAPY FOR TREATING CANCER COMPRISING AN IGF-1R INHIBITOR AND AN AKT INHIBITOR MERCK SHARP & DOHME CORP. (US) 2013-10-31 — — US disclosed
US-20130287763-A1 COMBINATION THERAPY FOR TREATING CANCER COMPRISING AN IGF-1R INHIBITOR AND AN AKT INHIBITOR MERCK SHARP & DOHME CORP. (US) 2013-10-31 — — US disclosed
US-20090253734-A1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME CORP. 2009-10-08 — — US disclosed
US-7589068-B2 Inhibitors of Akt activity MERCK & CO., INC. (US) 2009-09-15 — — US disclosed
US-7576209-B2 Inhibitors of Akt activity MERCK & CO., INC. (US) 2009-08-18 — — US disclosed
US-20090062327-A1 Inhibitors of AKT Activity MERCK SHARP & DOHME CORP. 2009-03-05 — — US disclosed
US-20080287457-A1 Inhibitors of Akt Activity MERCK SHARP & DOHME CORP. 2008-11-20 — — US disclosed
US-20080280899-A1 Inhibitors of Akt Activity MERCK SHARP & DOHME CORP. 2008-11-13 — — US disclosed
US-20080161317-A1 Inhibitors of Akt activity MERCK SHARP & DOHME LLC 2008-07-03 — — US disclosed
WO-2008070016-A2 INHIBITORS OF AKT ACTIVITY MERCK & CO., INC. (US) 2008-06-12 — — WO disclosed
WO-2008070134-A1 INHIBITORS OF AKT ACTIVITY MERCK & CO., INC. (US) 2008-06-12 — — WO disclosed
US-20080009507-A1 Inhibitors of Akt Activity MERCK SHARP & DOHME CORP. 2008-01-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230322724-A1 HETEROCYCLIC COMPOUNDS AS CBP/EP300 BROMODOMAIN INHIBITORS EP300, HDAC1, BRD3 ATR 1155/4885METAP1 3679/4885CYP17A1 3154/4885
US-20080161317-A1 Inhibitors of Akt activity PIK3CD, PIK3CA, PIK3CG ATR 834/4885METAP1 3039/4885CYP17A1 2340/4885
US-20080287457-A1 Inhibitors of Akt Activity AKT3, MTOR, STK3 ATR 267/4885METAP1 2773/4885CYP17A1 3742/4885
US-20080280899-A1 Inhibitors of Akt Activity AKT1, AKT2, AKT3 ATR 611/4885METAP1 1885/4885CYP17A1 4085/4885
US-20130287763-A1 COMBINATION THERAPY FOR TREATING CANCER COMPRISING AN IGF-1R INHIBITOR AND AN AKT INHIBITOR IGF1R, IGFBP1, IGFBP2 ATR 811/4885METAP1 2035/4885CYP17A1 3193/4885
US-20090062327-A1 Inhibitors of AKT Activity PIK3CD, PIK3CA, PIK3CG ATR 714/4885METAP1 2628/4885CYP17A1 2102/4885
US-20090253734-A1 INHIBITORS OF AKT ACTIVITY PIK3CD, PIK3CA, PIK3CG ATR 834/4885METAP1 3039/4885CYP17A1 2340/4885
US-20080009507-A1 Inhibitors of Akt Activity PIK3CD, PIK3CA, PIK3CG ATR 714/4885METAP1 2628/4885CYP17A1 2102/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.